.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AG08_Ocrelizumab.Ocrelizumab

Information

name:Ocrelizumab
ATC code:L04AG08
route:intravenous
n-compartments2

Ocrelizumab is a humanized monoclonal antibody targeting CD20-positive B-cells, used for the treatment of relapsing and primary progressive forms of multiple sclerosis (MS). It is approved by regulatory agencies including the FDA and EMA.

Pharmacokinetics

Population pharmacokinetic data in adult MS patients, both sexes, typically aged 18-55 years, with normal renal and hepatic function.

References

    Revisions

    Generated at 2025-07-21T18:21:10Z by OpenModelicaOpenModelica 1.25.1 using GenerateDoc.mos